Current News

Print version | PDF version | Send article | RSS feed

Targeted Genetics announces issuance of additional adeno-associated virus (AAV) vector technology patent

01 Sep 2005 - Targeted Genetics Corporation announced the issuance of an additional patent related to the Company's adeno-associated virus (AAV) vector technology. U.S. patent #6,936,466, titled "Transcriptionally Activated AAV Inverted Terminal Repeats (ITRs) for Use with Recombinant AAV Vectors" covers the use of small regulatory control elements in conjunction with sequences within the AAV genome to drive gene expression. The use of vectors described in the patent may help to maximize gene expression efficiency with little or no loss in viral payload.
 
"We believe that AAV vectors hold great promise in treating a wide variety of diseases," said H. Stewart Parker, President and Chief Executive Officer. "Targeted Genetics is pursuing several approaches, including the approach outlined in this patent, to expand the utility of AAV vectors. Utilizing sequences contained within the AAV genome to drive expression increases our flexibility with respect to vector design, which may allow us to deliver genes that might not ordinarily fit into a single AAV vector."